Dr. Rebecca J. Brown

Section on Translational Diabetes and Metabolic Syndromes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Building 10, Room 6-5940
10 Center Drive
Bethesda, Maryland 20892 (USA)

Web


Equipment and facilities

Inpatient and outpatient clinics. 
Metabolic nutrition facility with ability to conduct controlled diet studies. 
Hyperinsulinemic euglycemic clamps. 
Stable Isotope tracers for measurement of substrate flux. 
Energy expenditure via hood and room calorimetry and doubly labeled water. 
Research pharmacy for studies of investigational drugs.


Topics of interest

Effects of metreleptin in various forms of lipodystrophy.
Effects of metreleptin independent of food intake.
Effects of ApoCIII inhibition in partial lipodystrophy.
Pathophysiology of insulin resistance, dyslipidemia, and steatohepatitis in lipodystrophy,
and effect of leptin on this physiology.
Effects of leptin on reproductive dysfunction.
Pathway selective versus non-selective insulin resistance in various tissues in humans.



Publications

  • Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.  Metreleptin improves insulin sensitivity independent of food intake in humans with lipodystrophy. J Clin Invest. 2019 May;20(2):73-82.
  • Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage D, Long A, Fine G, Salinardi T, Gorden P. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.  Endocrine. 2019 May;20(2):73-82.
  • Oral EA, Gorden P, Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Brown RJ. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.  Endocrine. 2019 Feb 25. [Epub ahead of print]
  • Malandrino N, Reynolds JC, Brychta RJ, Chen KY, Auh S, Gharib AM, Startzell M, Cochran EK, Brown RJ. Visceral Fat Does Not Contribute to Metabolic Disease in Lipodystrophy. Obes Sci Pract. 2019 Jan 24;5(1):75-82. 
  • Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.   Effects of Metreleptin in Pediatric Patients with Lipodystrophy J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519.
  • Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother K, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016 Dec; 101(12):4500-4511.
  • Kassai A, Muniyappa R, Levenson AE, Walter MF, Abel BS, Ring M, Taylor SI, Biddinger SB, Skarulis MC, Gorden P, Brown RJ. Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients with Lipodystrophy. J Clin Endocrinol Metab. 2016 Apr;101(4):1790-7.
  • Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli A, Gautier JF, Vigouroux C, Gorden P.  Lymphoma in acquired generalized lipodystrophy.  Leuk Lymphoma. 2016 Jan;57(1):45-50.
  • Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.  Clinical Endocrinology.  2016 Jul;85(1):137-49.
  • Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.  J Clin Endocrinol Metab. 2015 May;100(5):1802-10.

 .